{"id":"nefopam-ampule","safety":{"commonSideEffects":[{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Sweating"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL465026","moleculeType":"Small molecule","molecularWeight":"253.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nefopam works by blocking the reuptake of multiple neurotransmitters at the synaptic level, thereby increasing their availability in the central nervous system. This monoamine reuptake inhibition enhances pain modulation pathways independent of opioid receptors. It is used primarily for moderate pain relief and has stimulant properties that may counteract opioid-induced sedation.","oneSentence":"Nefopam is a non-opioid analgesic that inhibits the reuptake of monoamines (norepinephrine, dopamine, and serotonin) in the central nervous system to produce analgesia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:44.914Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate acute and postoperative pain"},{"name":"Pain management as an adjunct or alternative to opioids"}]},"trialDetails":[{"nctId":"NCT05648058","phase":"PHASE3","title":"Role of Nefopam in Rituximab Transfusion Reaction","status":"UNKNOWN","sponsor":"Ministry Of Health / Nineveh Health Directorate","startDate":"2022-12-20","conditions":"Nefopam","enrollment":100},{"nctId":"NCT03626753","phase":"PHASE2, PHASE3","title":"Comparison of Two Routes of Administration of a Multimodal Analgesic Protocol in Postoperative Cesarean Section","status":"COMPLETED","sponsor":"Centre de Maternité de Monastir","startDate":"2015-01-01","conditions":"Cesarean Section; Complications, Wound, Infection (Following Delivery), Postoperative Pain, Spinal Anaesthesia During the Puerperium","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ACUPAN"],"phase":"phase_3","status":"active","brandName":"Nefopam ampule","genericName":"Nefopam ampule","companyName":"Ministry Of Health / Nineveh Health Directorate","companyId":"ministry-of-health-nineveh-health-directorate","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nefopam is a non-opioid analgesic that inhibits the reuptake of monoamines (norepinephrine, dopamine, and serotonin) in the central nervous system to produce analgesia. Used for Moderate acute and postoperative pain, Pain management as an adjunct or alternative to opioids.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}